Data on CMV infections after allogeneic PBCT (1995PBCT ( -1996 were reported from 48 centers: 352 pts (118 AML-33,5%; 70 ALL-19.9%; 75 CML-21%, 5 CLL-1.4%; 23 lymphomas-6.5%; 23 MDS-6.5%; 27 myelomas-7.7%; and 11 others-3.1%) received unmodified PBPC (uPBPC) and 116 (41 AML-35.3%; 15 ALL-12.9%; 26 CML-22.4%, 3 CLL-2.6%; 8 lymphomas-6.9%; 12 MDS-10.3%; 3 myelomas-2.6%; and 8 others-6.9%) CD34
CD34
+ cells/kg and 263 and 0.4 × 10 6 CD3 + cells/kg; 89% and 68% of donors were HLA-matched related, respectively. Prophylaxis of GvHD: CsA/MTX in 70% with uPBPC and 22% with CD34 + cells; no prophylaxis or CsA Ϯ prednisolone in 4/11% (uPBPC) and 10/51% (CD34 + ); 20/24% of donor-recipient pairs were CMV-seropositive, respectively. CMV drug prophylaxis by seropositivity was given in 28%, often combined with leukocyte filtration; Ig were given in 28%. The incidence of acute GvHD was (uPBPC/CD34): 0-36/48%; I-24/27%; II-19/14%; III-11/8%; IV-10/3%. The rates of chronic GvHD were: none-65/81% limited-20/15.5%; extensive-15/3.5%, respectively. Preemptive CMV-therapy with ganciclovir based on CMV pp65-antigenemia or PCR was used in 81/276 (29%) CMV-pos. pts with uPBPC and in 34/88 (37%) with CD34
+ . CMV-disease occured in CMVneg./pos. pts: with uPBPC in 2.8/5.4%, with CD34 + in 3.5/12.5%. In CMV-pos. pts with uPBPC 9 pneumonias, 1 gastroenteritis, 3 CNS-infections, and 1 myelo-suppression occurred; with CD34 + cells 10 CMV-pneumonias, 1 retinitis, and 1 cystitis were found. After a median follow up of 28 and 33 months, respectively 54% of the CMV-neg. pts and 58% of the CMV-pos. pts. transplanted with uPBPC were alive. In the CD34
+ cell group 64% of the CMV-neg. pts. and 49% of the CMV-pos. pts. survived at median of 31 and 24 months. Analysing all pts, the causes of death were (uPBPC/CD34 + ): CMV 2%/6%; other infection 10.2/15.5%; underlying disease 16.2/15.5%; GvHD and other complications 14.5/10.3%. We conclude, that the incidence of severe CMV-infections after PBPCT is limited. However lower CMV-related death rate with uPBPCT compared to CD34
+ selected and TCD transplants deserves further evaluation. Introduction: Infections are a major cause of morbidity and mortality in patients undergoing high dose therapy and subsequent autologous or allogeneic haemopoietic stem cell transplantation, despite the change from topical to systemic anti-infection prophylaxis and despite the introduction of growth factors and new antimicrobial drugs. 1 FUO and bacterial infection predominate during aplasia; allografted patients are highly endangered by systemic fungal infections.
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Patients: We report our single centre experience with data from 409 patients treated on our unit from its opening in 1990 until May 1997. 378 patients were transplanted for the first time, 12 patients were retransplanted or boosted. 19 patients were readmitted for miscellaneous reasons, 245 patients were allografted and 157 autografted. Antimicrobial prophylaxis was mainly quinolones, fluconazole plus amphotericin-B orally, aciclovir, and TMP/SMX or pentamidine. Results: 319 (78%) developed fever of significantly longer duration in the allogeneic setting and with anti-CMV seropositivity. The most frequent infection was fever of unknown origine (50.6%), followed by septicaemia (12.5%) and pneumonia (11.0%). Pathogens isolated in 24.6% of the infections were mostly gram positive bacteria (57.9%), followed by non-fermenting rods (11.2%) and Aspergillus spp. and Candida spp. (10.3%, each). Cumulative response rate to anti-microbial therapy was 66.9%. Infections were responsible for 62.5% (25/40) of deaths after transplantation. Predominant pathogens were Aspergillus spp. (11), Candida spp. (4), and Pseudomonas spp. (3). None of the patients died from gram positive bacterial infection. The risk of dying from infection was 11.2% after allografting and 0.8% after autotransplantation. Discussion: Infections remain a major risk for early death after allogeneic transplantation of haemopoietic stem cells. Infection with gram negative bacteria can be prevented by quinolone prophylaxis. Predominant pathogens of lethal infections are Aspergillus spp., Candida spp., and non-fermenting rods. Systemic infection with these pathogens is associated with a poor prognosis. 
S8c: Triple Sudden Cardiac Arrest in a Young, Healthy Donor During Bone Marrow Harvesting in General Anaesthesia
The harvesting of the bone marrow cells from a donor for their transplantation is generally considered as a safe procedure. Nevertheless it should be remembered, that lifethreatening complications although rare can occur. In our case the bone marrow was collected during general anaesthesia from 28 years old man, untill now healthy, without symptoms and signs in the clinical examination and with no abnormalities in the screening tests.
General anaesthesia was performed with thiopental 350 mg and succinylocholin 100 mg. For myorelaxation norcuron 8 mg and for continuation of the procedure oxygen and nitrous oxide /2: 4/ as well as halotan 0,4 vol% were used. 30 min. from the onset of the procedure sudden cardiac arrest appeared in mechanism of asystolia. Indirect mechanical massage, double injections of adrenalin /2 mg/ helped to bring him back to sinus rythm. After several minutes cardiac arrest occured once again and the same treatment was successful. However one minute later third circulatory arrest resulting from ventricular fibrillation occured. Double defibrillation wasn't helpful and finally injection of 300 mg amiodarone and 200 mg xylocaine overcame the problem and returned the sinus rythm.
The whole resuscitation process lasted appr. 30 minutes.
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The harvesting of bone marrow has been continued and completed successfully. There were however some problems with the patient's weaning. After the procedure he remained intubated in deep sleep with some signs of brain damage through ten hours. Then suddenly he woke up, extubated by himself and tried to recognize conciously his situation. We did not observe late consequences of this serious complication. The transplantation of his bone marrow to a brother suffering from paroxysmal nocturnal hemoglobinuria was successful. Hepatic veno-occlusive disease is one of the fatal complications of bone marrow-and stem cell transplantations. Patients and methods: Between January 1997 and December 1998 133 patients underwent BMT/PBSCT at the University of Leipzig. Five patients (3.6%) developed a VOD. In four patients TIPS for the management of the VOD was performed. 3 patients had autologous PBSCT and one allo-BMT(UD)id. Conditioning regimes were BU (2), BuThCtx(1), BuCtxATG (1). Diagnoses of VOD was considered in patients who developed painful hepatomegaly, ascites and hyperbilirubinemia within 3-5 weeks after BMT. One patient had a rapid rise of ALT. Radiologicaly all patients had a homogeneous hepatomegaly with well contrasted large liver veins on CT and 3 of 4 patients had a pendular or retrograde flow in the portal vein. Mean portal pressure gradient pre TIPS was 25mmHg (range 8-33). Liver biopsies were performed in 3 of 4 of the patients and confirmed the clinical diagnosis. Results: Two of four Patients had a good regression of their symptoms 7 and 8 days after TIPS and have a normal liver function 10 and 15 month after TIPS. In these two patients a significant decrease of the portal vein gradient could be reached. One patient died 4 days after TIPS due to a progressive liver dysfunction without a benefit. The patient with the lowest portal vein gradient (8 mmHg) had a stable VOD after TIPS and died day +87 after allo-BMT(UD)id due to an other complication unrelated to VOD. No induced encephalopathy was observed. Summary: In severe VOD with high portal venous gradient TIPS to be considered as a treatment option.
